Skip to main content
SpringerLink
Log in

Ability of Doxorubicin-Loaded Nanoparticles to Overcome Multidrug Resistance of Tumor Cells After Their Capture by Macrophages

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. Investigation of the ability of doxorubicin-loaded nanoparticles (NP/Dox) to overcome multidrug resistance (MDR) when they have first been taken up by macrophages.

Methods. The growth inhibition of P388 sensitive (P388) and resistant (P388/ADR) tumor cells was evaluated in a coculture system consisting of wells with two compartments. The tumor cells were seeded into the lower compartment, the macrophages were introduced into the upper part in which the drug preparations were also added.

Results. Doxorubicin exerted lower cytotoxicity on tumor cells in coculture compared with direct contact. In P388/ADR, NP/Dox cytotoxicity was far higher than that of free doxorubicin (Dox). Three different formulations of cyclosporin A (either free (CyA), loaded to nanoparticles (NP/CyA) or in a combined formulation with doxorubicin (NP/Dox-CyA)), were added to modulate doxorubicin efficacy. The addition of cyclosporin A to Dox increased drug cytotoxicity. Both CyA added to NP/Dox and NP/Dox-CyA were able to bypass drug resistance.

Conclusions. Despite the barrier role of macrophages, NP/Dox remained far more cytotoxic than Dox against P388/ADR. Both NP/ Dox + CyA and NP/Dox-CyA allowed to overcome MDR, but the last one should present greater advantagein vivo by confining both drugs in the same compartment, hence reducing the adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. N. Chiannilkulchai, Z. Driouich, J. P. Benoit, A. L. Parodi, and P. Couvreur. Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases. Sel. Cancer. Ther. 5:1–11 (1989).

    Google Scholar 

  2. K. Yachi, N. Suzuki, N. Tanaka, K. Okada, I. Mitsui, Y. Kawato, Y. Komagata, K. Komiyama, and H. Kikuchi. The effect of adriamycin against a liver metastatic model by encapsulation in liposomes. Biopharm. Drug Dispos. 17:699–715 (1996).

    Google Scholar 

  3. C. Cuvier, L. Roblot-Treupel, J. M. Millot, G. Lizard, S. Chevillard, M. Manfait, P. Couvreur, and M. F. Poupon. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol. 44:509–517 (1992).

    Google Scholar 

  4. S. Bennis, C. Chapey, P. Couvreur, and J. Robert Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumor cells in culture. Eur. J. Cancer 30A:106–111 (1993).

    Google Scholar 

  5. A. Colin de Verdière, C. Dubernet, F. Nemati, E. Soma, M. Appel, J. Ferté, S. Bernard, F. Puisieux, and P. Couvreur. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br J Cancer 76:198–205 (1997).

    Google Scholar 

  6. J. A. Kellen. The reversal of multidrug resistance in cancer. Anticancer Res. 13:959–961 (1993).

    Google Scholar 

  7. G. Toffoli, G. Corona, R. Sorio, A. Bertola, and M. Boiocchi. Reversal activity of cyclosporin A and its metabolites M1 M17 and M21 in multidrug-resistant cells. Int. J. Cancer 71:900–906 (1997).

    Google Scholar 

  8. R. C. Maia, M. K. Carrico, C. E. Klumb, H. Noronha, A. M. Coelho, F. C. Vaasconcelos, and V. M. Ruimanek. Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide. J. Exp. Clin. Cancer Res. 16:419–424 (1997).

    Google Scholar 

  9. M. L. Den Boer, R. Pietres, K. M. Kazemier, G. E. Janka-Schaub, G. Henze, and A. J. Veerman. The modulating effect of PSC833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia. Leukemia 12:912–920 (1998).

    Google Scholar 

  10. N. Chiannilkulchai, N. Ammoury, B. Caillou, J. Ph. Devissaguet, and P. Couvreur. Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M5076 metastasis-bearing mice. Cancer Chemoter. Pharmacol. 26:122–126 (1990).

    Google Scholar 

  11. T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55–63 (1983).

    Google Scholar 

  12. F. Martin, A. Caignard, O. Olsson, J. F. Jeannin, and A. Leclerc. Tumoricidal effect of macrophages exposed to adriamycin in vivo or in vitro. Cancer Res. 42:3851–3857 (1982).

    Google Scholar 

  13. Y. Adachi, S. Arii, N. Funaki, H. Higashitsuji, S. Fujita, M. Furutani, M. Mise, W. Zhang, and T. Tobe. Tumoricidal activity of Küpffer cells augmented by anticancer drugs. Life Sci. 51:177–183 (1992).

    Google Scholar 

  14. B. Ryffel, M. J. Mihatsch, and G. L. Fisher. Immunosuppression and cancer: the ciclosporin case. Drug Chem. Toxicol. 15:95–115 (1992).

    Google Scholar 

  15. R. Fernandez-Urrusuno, E. Fattal, J. M. Rodrigues Jr., J. Féger, P. Bedossa, and P. Couvreur. Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. J. Biomed. Mat. Res. 31:401–408 (1996).

    Google Scholar 

  16. G. Storm, P. A. Steerenberg, F. Emmen, M. van Borssum Waalkes, and D. J. A. Crommelin. Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. Biochim. Biophys. Acta 965:136–145 (1988).

    Google Scholar 

  17. J. Andersson, S. Nagy, C. G. Groth, and U. Andersson. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunology 75:136–142 (1992).

    Google Scholar 

  18. H. Hölschermann, F. Dürfeld, U. Maus, A. Bierhaus, K. Heidinger, J. Lohmeyer, P. P. Nawroth, H. Tillmanns, and W. Haberbosch. Cyclosporine A inhibits tissue factor expression in monocytes/macrophages. Blood 88:3837–3845 (1996).

    Google Scholar 

  19. M. Conde, J. Andrade, F. J. Bedoya, C. Santa Maria, and F. Sobrino. Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity. Immunology 84:476–481 (1995).

    Google Scholar 

  20. Y. Hattori and N. Nakanishi. Effects of cyclosporin A and FK506 on nitric oxide and tetrahydrobiopterin synthesis in bacterial lipopolysaccharide-treated J774 macrophages. Cell Immunol. 165:7–11 (1995).

    Google Scholar 

  21. T. Tojimbara, L. E. Bermudez, H. Egawa, M. Hayashi, S. K. So, and C. O. Esquivel. Cyclosporine and tacrolimus both suppress activation of Küpffer cells in vitro. Transplant Proc. 28:1381–1382 (1996).

    Google Scholar 

  22. C. E. Soma, C. Dubernet, and P. Couvreur. Investigation of macrophage role in the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro, Proc. 2nd World Meeting APGI/APV, Paris, 25–28 May, p. 635 (1998).

Download references

Author information

Authors and Affiliations

  1. Centre d'Etudes Pharmaceutiques, UMR CNRS 8612, 5 rue J.B. Clément, 92296, Châtenay-Malabry Cedex, France

    Claire Emilienne Soma, Catherine Dubernet, Gillian Barratt, Martine Appel & Patrick Couvreur

  2. Institut Curie, Section Recherche, 26 rue d'Ulm, 75248, Paris Cedex 05, France

    Fariba Nemati

  3. Department of Pharmaceutics, School of Pharmacy, The Hebrew University of Jerusalem, P.O.B. 12065, Jerusalem, 91120, Israel

    Simon Benita

  4. David R. Bloom Center for Pharmacy of the Hebrew University of Jerusalem, Israel

    Simon Benita

Authors
  1. Claire Emilienne Soma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine Dubernet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gillian Barratt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fariba Nemati
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martine Appel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Simon Benita
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Patrick Couvreur
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherine Dubernet.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Soma, C.E., Dubernet, C., Barratt, G. et al. Ability of Doxorubicin-Loaded Nanoparticles to Overcome Multidrug Resistance of Tumor Cells After Their Capture by Macrophages. Pharm Res 16, 1710–1716 (1999). https://doi.org/10.1023/A:1018902031370

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018902031370

Search

Navigation